23 February 2006

Joseph C. Yarze – 23 February 2006

Silvio Nadalin, Massimo Malagó, Giuliano Testa, Randolph Schaffer, Georgios C. Sotiropoulos, Andrea Frilling, Christoph E. Broelsch – 23 February 2006 – In this study, we present our experience with 4 healthy donors having the rare condition of “hepar divisum” after the intraoperative death of the recipient of an intended right adult living donor liver transplantation (LDLT). The study included 4 donors and 4 intended right LDLT recipients affected by neuroendocrine tumor (n = 2), hepatocellular carcinoma (n = 1), and cryptogenic cirrhosis (n = 1). All 4 recipients died intraoperatively.

Shahid Habib, Obaid Shakil, Osvaldo F. Couto, Anthony J. Demetris, John J. Fung, Amadeo Marcos, Kapil Chopra – 23 February 2006 – Caroli's disease is a rare congenital hepatic disease, characterized by segmental dilatation of the biliary tree. Patients who have recurrent bouts of biliary infection, particularly those with complications related to portal hypertension, may require orthotopic liver transplantation (OLT). Few case reports have described the outcome of OLT in patients with Caroli's disease and to date there is no large series reported in the literature.

Takehisa Ueno, Greg Jones, Adrian Martin, Toru Ikegami, Edmund Q. Sanchez, Srinath Chinnakotla, Henry B. Randall, Marlon F. Levy, Robert M. Goldstein, Goran B. Klintmalm – 23 February 2006 – Hepatic artery stenosis after liver transplantation may affect liver function and result in hepatic artery thrombosis. Surgical reconstruction has been the first choice for treatment. Interventional radiologic technique can be used, but there is no report on long‐term outcome. The aim of this paper is to assess current outcome and complications of hepatic artery stenting.

Raymond Reding, Jérémie Gras, Dinh Quang Truong, Grégoire Wieërs, Dominique Latinne – 23 February 2006 – The aim of this work is to review the current knowledge in the field of immunological monitoring of allogenic responsiveness in clinical liver transplantation. When compared to other solid‐organ transplants, liver allografts are considered as immunologically privileged, and, accordingly, constitute a favorable setting to develop experimental as well as clinical strategies for minimization of immunosuppression and even induction of operational tolerance.

Lucy Golden‐Mason, Hugo R. Rosen – 23 February 2006 – Liver cirrhosis and hepatocellular carcinoma secondary to chronic hepatitis C virus (HCV) infection requiring transplantation represents a significant public health problem. The most remarkable feature of hepatitis C virus is the ability to establish chronic infection in the vast majority of cases. Efforts to define clinical correlates of HCV persistence have focused primarily on CD4 and CD8 T cell responses. Until recently, the role of innate immunity in determining the outcome of HCV infection had received relatively little attention.

Hironori Haga, Hiroto Egawa, Yasuhiro Fujimoto, Mikiko Ueda, Aya Miyagawa‐Hayashino, Takaki Sakurai, Tomoko Okuno, Itsuko Koyanagi, Yasutsugu Takada, Toshiaki Manabe – 23 February 2006 – Complement C4d deposition in graft capillaries has been reported to be associated with antibody‐mediated rejection in kidney and other solid organ transplantation. The correlation of C4d deposits and humoral rejection in liver transplants, however, is not well understood.

Ulf P. Neuman, Peter Neuhaus – 23 February 2006

Neal R. Barshes, Timothy C. Lee, Ian W. Udell, Christine A. O'Mahoney, Saul J. Karpen, Beth A. Carter, John A. Goss – 23 February 2006 – The pediatric end‐stage liver disease (PELD) model accurately estimates 90‐day waitlist mortality for pediatric liver transplant candidates, but it has been unclear if PELD can identify patients who will derive survival benefit from undergoing liver transplantation (LT), if it correlates with posttransplant survival, or if it can identify patients for whom LT would be futile.